Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 250

The DOI matches its Crossref record.

Vemurafenib Redifferentiation of BRAF Mutant, RAI-Refractory Thyroid Cancers

Open access
Dunn, Lara A, Sherman, Eric J, Baxi, Shrujal S, Tchekmedyian, Vatche, Grewal, Ravinder K, Larson, Steven M, Pentlow, Keith S, Haque, Sofia, Tuttle, R Michael, Sabra, Mona M, Fish, Stephanie, Boucai, Laura, Walters, Jamie, Ghossein, Ronald A, Seshan, Venkatraman E, Ni, Ai, Li, Duan, Knauf, Jeffrey A, Pfister, David G, Fagin, James A, Ho, Alan L · 2019 · The Journal of Clinical Endocrinology & Metabolism

Abstract

CONTEXT: BRAFV600E mutant thyroid cancers are often refractory to radioiodine (RAI). OBJECTIVES: To investigate the utility and molecular underpinnings of enhancing lesional iodide uptake with the BRAF inhibitor vemurafenib in patients with RAI-refractory (RAIR). DESIGN: This was a pilot trial that enrolled from June 2014 to January 2016. SETTING: Academic cancer center. PATIENTS: Patients with RAIR, BRAF mutant thyroid cancer. INTERVENTION: Patients underwent thyrotropin-stimulated iodine-124 (124I) positron emission tomography scans before and after ~4 weeks of vemurafenib. Those with increased RAI concentration exceeding a predefined lesional dosimetry threshold (124I responders) were treated with iodine-131 (131I). Response was evaluated with imaging and serum thyroglobulin. Three patients underwent research biopsies to evaluate the impact of vemurafenib on mitogen-activated protein kinase (MAPK) signaling and thyroid differentiation. MAIN OUTCOME MEASURE: The proportion of patients in whom vemurafenib increased RAI incorporation to warrant 131I. RESULTS: Twelve BRAF mutant patients were enrolled; 10 were evaluable. Four patients were 124I responders on vemurafenib and treated with 131I, resulting in tumor regressions at 6 months. Analysis of research tumor biopsies demonstrated that vemurafenib inhibition of the MAPK pathway was associated with increased thyroid gene expression and RAI uptake. The mean pretreatment serum thyroglobulin value was higher among 124I responders than among nonresponders (30.6 vs 1.0 ng/mL; P = 0.0048). CONCLUSIONS: Vemurafenib restores RAI uptake and efficacy in a subset of BRAF mutant RAIR patients, probably by upregulating thyroid-specific gene expression via MAPK pathway inhibition. Higher baseline thyroglobulin values among responders suggest that tumor differentiation status may be a predictor of vemurafenib benefit.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/jc.2018-01478

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 250

Metadata

Authors
Dunn, L. A., Sherman, E. J., Baxi, S. S., Tchekmedyian, V., Grewal, R. K., Larson, S. M., Pentlow, K. S., Haque, S., Tuttle, R. M., Sabra, M. M., Fish, S., Boucai, L., Walters, J., Ghossein, R. A., Seshan, V. E., Ni, A., Li, D., Knauf, J. A., Pfister, D. G., Fagin, J. A., & Ho, A. L.
Venue
The Journal of Clinical Endocrinology & Metabolism
Published
2018-09-25
Volume
104
Issue
5
Pages
1417-1428
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
OpenAlex
W2894264092
Cited by
250
References
0
FWCI
13.30
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Vemurafenib Redifferentiation of BRAF Mutant, RAI-Refractory Thyroid Cancers. https://app.cochat.ai/papers/10.1210/jc.2018-01478
The paper
Dunn, L. A., Sherman, E. J., Baxi, S. S., Tchekmedyian, V., Grewal, R. K., Larson, S. M., Pentlow, K. S., Haque, S., Tuttle, R. M., Sabra, M. M., Fish, S., Boucai, L., Walters, J., Ghossein, R. A., Seshan, V. E., Ni, A., Li, D., Knauf, J. A., Pfister, D. G., . . . Ho, A. L. (2019). Vemurafenib Redifferentiation of BRAF Mutant, RAI-Refractory Thyroid Cancers. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.2018-01478

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.